Several lines of evidence suggest that targeting the body’s defense pathways might help treat a subset of people with the psychiatric disorder. But many open questions remain.
Several lines of evidence suggest that targeting the body’s defense pathways might help treat a subset of people with the psychiatric disorder. But many open questions remain.
Several lines of evidence suggest that targeting the body’s defense pathways might help treat a subset of people with the psychiatric disorder. But many open questions remain.
Making specific alterations to the bacterial population in a rat’s lungs either better protects the animals against multiple sclerosis–like symptoms or makes them more vulnerable, a study finds—the first demonstration of a lung-brain axis.
Immunologists and parasitologists are working to revive the idea that helminths, and more specifically the molecules they secrete, could help treat allergies and autoimmune disease.
The Scientist spoke with Rachel Zeig-Owens, the director of epidemiology for the World Trade Center Health Program, about what scientists have learned after two decades of studying illness and disease among survivors.
When researchers injected mice with antibodies from fibromyalgia patients, the animals developed symptoms of the disease—suggesting that it may be controlled by the immune system, not the nervous system.
Stronger interferon production, greater T cell activation, and increased susceptibility to autoimmunity are just some of the ways that females seem to differ from males.
The Johns Hopkins University researcher bucked the prevailing idea that the body would not launch an immune response against its own tissues, and in doing so established an entirely new scientific discipline.
A handful of viruses have been associated with long-term, debilitating symptoms in a subset of those who become infected. Early signs hint that SARS-CoV-2 may do the same.
Many dominant T cell variants decline during pregnancy and reappear afterward, possibly explaining why relapses of the autoimmune disease are less common when women are expecting.
A Chicago-based center that has long operated a clinical trial program for stem cell therapies, has stopped recruiting further patients as its chief, Richard Burt, leaves for a research sabbatical.